LOS ANGELES, Oct. 12, 2017 /PRNewswire/ -- CytRx Corporation
(NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, today highlighted that
aldoxorubicin licensee NantCell, Inc., a private subsidiary of
NantWorks, LLC, has informed the Company that it plans to submit
Investigational New Drug (IND) applications combining aldoxorubicin
with its immunotherapy protocols for clinical trials
addressing patients diagnosed with Pancreatic and Breast
cancer.
The planned clinical trials will enroll patients with cancers
that are no longer responding, or never responded, to standard
therapy and have progressed. The clinical trials will employ
an adaptive design which will allow for expansion of treatment
cohorts and modification of patient treatments based on tumor
profiling and individual patient responses over time.
"The inclusion of aldoxorubicin in NantCell's upcoming pending
IND filings is important validation of its potential ability to
provide benefit for patients with advanced-stage, difficult to
treat cancers," commented Steven A.
Kriegsman, CytRx's Chairman and Chief Executive
Officer. "These planned trials allow for the continued
development of aldoxorubicin in patient populations with great
needs for transformation in cancer care."
About CytRx Corporation
CytRx Corporation is a
biopharmaceutical company specializing in research and clinical
development of novel anti-cancer drug candidates that employ linker
technologies to enhance the accumulation and release of drug at the
tumor. Aldoxorubicin, CytRx's most advanced drug conjugate, is an
improved version of the widely used chemotherapeutic agent
doxorubicin and has been out-licensed to NantCell, Inc. CytRx
is also rapidly expanding its pipeline of ultra-high potency
oncology candidates at its laboratory facilities in
Freiburg, Germany, through its LADR™ (Linker Activated Drug
Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies.
About NantCell, Inc.
NantCell, an entity controlled
by Dr. Patrick Soon-Shiong, is an
immuno-oncology company focused on the discovery of innovative
antibody, T cell and NK cell based treatments by developing
molecularly targeted therapeutics, based on the proteomic profile
of the patient's tumor, independent of the cancer's anatomical
type.
NantCell's mission is to make obsolete the standard method of
clinical trial design of "trial and error" and replace it with a
level of quantitative predictability based on both the genomic and
proteomic profile performed a priori. The Company will tap into
comprehensive "omic" analytic tools and "big data" generated from
supercomputing to develop molecularly designed drugs in this era of
genomics and proteomics and identify patients and their tumor
signature at the most granular cellular, DNA and protein levels.
Patients entering clinical trials would be identified after a
comprehensive "omic" analysis from tissue to cell to DNA to RNA to
protein to peptide to drug, and tested based on this molecular
profile to maximize clinical outcome and minimize side
effects. Through these integrated diagnostic methods,
the company is pursuing the vision of treating the biology of
cancer rather than the anatomy, and drive the immune system
inherited by all to defeat cancer. For more information
please visit www.nanthealth.com and follow Dr. Soon-Shiong on
Twitter @Dr.PatSoonShiong.
Forward-Looking Statements
This press release
contains forward-looking statements. Such statements involve risks
and uncertainties that could cause actual events or results to
differ materially from the events or results described in the
forward-looking statements, including risks and uncertainties
relating to plans for regaining compliance with the NASDAQ rules
and higher share price of our common stock; the ability of
NantCell, Inc., to obtain regulatory approval for its products that
use aldoxorubicin; the ability of NantCell, Inc., to manufacture
and commercialize products or therapies that use aldoxorubicin; the
amount, if any, of future milestone and royalty payments that we
may receive from NantCell, Inc.; our ability to develop new
ultra-high potency drug candidates based on our
LADRTM technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-inclusion-of-aldoxorubicin-in-pending-upcoming-clinical-trial-submissions-planned-by-licensee-nantcell-inc-300535444.html
SOURCE CytRx Corporation